FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the inception of the “FDB Centre of Excellence in Bioprocessing 2.0.” (CEB) in the United Kingdom. This initiative is an extension of Fujifilm’s global innovation initiatives. The Centre of Excellence will be led and funded by FUJIFILM Diosynth Biotechnologies, in partnership with leadingacademic institutions – University of Edinburgh; and University of...
Ivan McKee MSP, Minister for Trade, Investment and Innovation, launches plan to 450 delegates at IBioIC Annual Conference Minister for Trade, Investment and Innovation, Ivan McKee MSP, has today (Thursday 31st January) launched an updated National Plan for Industrial Biotechnology (IB), which aims to boost industry growth and innovation while also raising public awareness of IB as a technology which can help deliver a sustainable...
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces that the Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND/CTA) for its lead candidate MGB-BP-3. The Company intends to commence its dose-range finding Phase IIa clinical trial, in the US and Canada, on MGB-BP-3 for the treatment of Clostridium...
The long-awaited Bio-economy Strategy has finally been published. IBioIC CEO Roger Kilburn shares his thoughts on this important document. I commend the publication in December, by the UK Government of the long awaited Bio-economy Strategy entitled “Growing the bio-economy”. It sets out the blueprint, in 15 actions, for transforming the UK economy through the power of bioscience and biotechnology with the ambition to double the...
This acquisition will add early Stage API and Finished Dosage Form Development & Testing Services to its Global Contract Development & Manufacturing Network. Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced it has entered into a definitive agreement to acquire Avista Pharma Solutions (Avista), a contract development, manufacturing, and testing...
BioFilm has secured a £2.5 million funding package which will be invested in new product development and laboratory facilities along with further state-of-the-art manufacturing technology at its premises in Blantyre, Scotland. Ian Stevens, CEO of BioFilm Ltd, said “This funding package will be instrumental in the expansion of our modern manufacturing equipment and product development facilities.” The firm which was originally launched as a subsidiary of food products firm Devro, specialises in fast...
Our approach to implementing the next phase of the Life Sciences Strategy is crucial to maintaining the momentum that keeps us on the path towards our bold target for life sciences set almost two years ago. There are global changes taking place in the sector with a greater industrialisation of manufacturing process and changes to R&D investment by global life science companies. I am confident...
On Monday 12th November the sector came together to discuss how Scotland can ‘Move Forward Together to 2025 and beyond ’at the annual Scotsman Life Science conference. New figures published on Monday showed that turnover in the Life Sciences sector stood at £5.2 billion in 2016. This confirms the high growth of the life sciences sector since 2010, putting it on track to reach the...
The new directory called Scottish Health Research and Innovation Ecosystem launched today at the annual Life Science Scotland conference in Glasgow by Dave Tudor, Co-Chair of the Life Sciences Scotland Industry Leadership Group (LSS) as he discusses the importance of Momentum and Collaboration within the industry. This tool will facilitate essential collaboration between the NHS and other life sciences organisations in Scotland. A greatly simplified search...
Scotland’s life sciences community will come together again this month to set a course for the industry to meet its ambitious turnover target of £8 billion by 2025. The title of the event, Moving Forward Together: To 2025 and Beyond captures the two key themes: momentum and collaboration. Currently, the most up-to-date figures for the life sciences sector in Scotland are from 2015 and show...